Consensus Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
1.56 ^USD	-4.29%		0.00%	-78.78%

May. 07	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Evolution of the average Target Price on Immuneering Corporation

Price target over the last 5 years

History of analyst recommendation changes

c676122b2.iFuPmy6nTpOMMYytPNmC6NXJC2oD0iG2-34OpvhxHe8.sTHhqBzWD9vLWMTMbIPBkOOcMy1p63OHjRZ-7YFCVr7qLeCjV4oJx_8FzQ~ea8e094a8df5039b08ef16fed163f0d0

Analyst Recommendations on Immuneering Corporation

Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	Apr. 02	MT
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16	Mar. 15	MT
Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating	Mar. 15	MT
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating	Mar. 15	MT
Guggenheim Downgrades Immuneering to Neutral From Buy	Mar. 15	MT
TD Cowen Downgrades Immuneering to Market Perform From Outperform	Mar. 15	MT
Needham Starts Coverage on Immuneering with Buy Rating, $20 Price Target	Dec. 01	MT
Morgan Stanley Upgrades Immuneering to Equalweight From Underweight, Adjusts Price Target to $14 From $5	23-04-19	MT
Mizuho Upgrades Immuneering to Buy From Neutral, Adjusts Price Target to $20 From $10	23-04-19	MT
Chardan Raises Price Target on Immuneering to $22 From $18, Maintains Buy Rating	23-04-19	MT
Mizuho Initiates Immuneering at Neutral With $10 Price Target	23-03-30	MT
Morgan Stanley Downgrades Immuneering to Underweight From Equal Weight, Adjusts Price Target to $5 From $12	23-02-03	MT
Morgan Stanley Adjusts Price Target for Immuneering to $12 From $18, Maintains Equalweight Rating	22-07-14	MT
Chardan Capital Initiates Immuneering at Buy with $18 PT on Pipeline Potential, Translational Bioinformatic Platform	22-07-08	MT
Chardan Capital Initiates Immuneering at Buy with $18 Price Target	22-07-08	MT
Oppenheimer Initiates Coverage on Immuneering With Outperform Rating, $26 Price Target	22-04-01	MT
Piper Sandler Starts Immuneering at Overweight With $41 Price Target	22-01-07	MT
Guggenheim Adjusts Price Target for Immuneering to $30 From $42, Maintains Buy Rating	22-01-03	MT
IMMUNEERING : Cowen Starts Immuneering at Outperform	21-08-24	MT
IMMUNEERING : Guggenheim Starts Immuneering at Buy with $42 Price Target	21-08-24	MT
IMMUNEERING : Jefferies Starts Immuneering at Buy With $50 Price Target	21-08-24	MT
IMMUNEERING : Morgan Stanley Starts Immuneering at Equal-Weight With $39 Price Target	21-08-24	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.56 USD

Average target price

15.14 USD

Spread / Average Target

+870.70%

High Price Target

25 USD

Spread / Highest target

+1,502.56%

Low Price Target

4 USD

Spread / Lowest Target

+156.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immuneering Corporation

Mizuho Securities
Jefferies & Co.
Needham & Co.
Chardan Research
TD Cowen
Guggenheim
Morgan Stanley
Oppenheimer
Piper Sandler
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar